Clinical Scorecard: Low-Dose Atropine: Beyond Refraction
At a Glance
| Category | Detail |
|---|---|
| Condition | Childhood Myopia Management |
| Key Mechanisms | Reduces myopia progression through modulation of axial growth. |
| Target Population | Children aged 3–14 years with documented myopia progression. |
| Care Setting | Ophthalmology clinics and pediatric care. |
Key Highlights
- Low-dose atropine can reduce myopia progression, but efficacy varies by concentration.
- 0.05% atropine generally shows the strongest efficacy among low-dose options.
- Adverse events reported in 35% of children treated with 0.03% atropine.
- Current evidence does not support a universal dosing recommendation.
- 0.01% atropine is a modest option whose effectiveness depends on baseline risk.
Guideline-Based Recommendations
Diagnosis
- Documented progression of at least 0.5 D per year in myopia.
Management
- Consideration of different concentrations of atropine (0.01%, 0.025%, 0.03%, 0.05%) based on individual patient needs.
Monitoring & Follow-up
- Track axial growth and refractive changes over time.
Risks
- Adverse events may occur, leading to treatment discontinuation.
Patient & Prescribing Data
Children aged 3–14 years with myopia between −0.5 D and −6.0 D.
0.01% atropine is often viewed as a safe default but may not sufficiently slow axial elongation.
Clinical Best Practices
- Evaluate individual patient baseline progression and treatment targets before prescribing.
- Utilize trajectory-based endpoints for assessing treatment success.
- Ensure standardized formulations for improved quality control.
Related Resources & Content
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
